FROM CODE TO CURE. Corporate Overview. November Anat Cohen-Dayag, PhD President & CEO.
|
|
- Lambert Beasley
- 5 years ago
- Views:
Transcription
1 FROM CODE TO CURE TM Corporate Overview November 217 Anat Cohen-Dayag, PhD President & CEO 1
2 SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Forward-looking statements can be identified by the use of terminology such as will, may, expects, anticipates, believes, potential, plan, goal, estimate, likely, should, and intends, and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen s business model is substantially dependent on entering into collaboration agreements with third parties, and Compugen may not be successful in generating adequate revenues, or commercializing aspects of its business model. Compugen also may not meet expected milestones in its development pipeline. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen s most recent Annual Report on Form 2-F as filed with the Securities and Exchange Commission ( SEC ) as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen s views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law. Certain studies and data presented herein have been conducted for us by other entities as indicated where relevant. All intellectual property, including trade marks, trade names, slogan, logos, service marks, patents, copyrights or trade secret displayed in this presentation, including the name Compugen, are registered and unregistered intellectual property rights of Compugen. 2 2
3 FROM CODE TO CURE TM Our Vision Transforming patient lives by developing first-in-class therapeutics based on computational predictive discovery of novel targets 3
4 Overall Response Rate % MARKET OPPORTUNITY: 7-8% OF PATIENTS NON- RESPONSIVE TO APPROVED IMMUNOTHERAPIES ~2% Average Response Rate Gap to Bridge Approved indications In clinical testing TARGETING NEW IMMUNE CHECKPOINT PATHWAYS MAY ADDRESS NON-RESPONSIVE PATIENT POPULATION 4 4
5 KEY HIGHLIGHTS 1 Diversified pipeline of novel targets and therapeutic candidates Novel immune checkpoint targets including PVRIG, TIGIT and myeloid candidates Potential for PD-L1 non-responsive patients and/or for combination with existing therapies 2 3 Transitioning to a clinical stage company with lead asset PVRIG mab (COM71) IND expected towards end of Q1 218, Phase 1 open-label study to begin in 218 Synergy with both TIGIT and PD-1/L1 blockers Broadly applicable predictive discovery capabilities Continuous discovery of novel targets for internal development or collaborations Immune tolerance mechanism may represent next generation treatment for autoimmune diseases 4 World class scientific advisory team and collaboration partners Long term research collaborations with Johns Hopkins and Mount Sinai Development collaboration and license agreement with Bayer 5 5
6 COMPUGEN S PIPELINE PROGRAM From Code to Cure Target discovery Target validation mab discovery Screening/lead selection Cell line developmnt CMC/IND enabling IND Filing IMMUNO-ONCOLOGY COM71 / PVRIG end of Q1 218 CGEN-151T COM92 / TIGIT in 219 CGENXXXX / Myeloid Other programs AUTOIMMUNE CGEN Programs, from computer prediction to preclinical POC 6 6
7 BUILDING THE COMPUGEN IO PIPELINE: ADDING MULTIPLE MECHANISMS TO BROADLY ADDRESS CANCER TREATMENT COM71 Tumor/ APC PVRL2 DNAM PVR COM92 PVRIG TIGIT T Cell - PD-1 CGEN-XXXX PD-L1 Tumor/ APC ADDRESS VARIOUS IMMUNE SUPRESSIVE COMPONENT IN THE TME 7 7
8 APPLYING OUR PREDICTIVE APPROACH TO IMMUNE CHECKPOINT DISCOVERY CGEN novel targets A DISCOVERY ENGINE TO REPLENISH PIPELINE WITH NEW DRUG PROGRAMS 8 8
9 PVRIG BLOCKADE IS DIFFERENT FROM AND SYNERGISTIC WITH TIGIT BLOCKADE Separate inhibitory pathways Different temporal and spatial distribution of targets and ligands KEY FINDINGS PVRIG high T cell activation PVRIG is expressed in tumor microenvironment (CD8/TILs) Co-expressed in multiple tumor types with other checkpoints (TIGIT/PD-1) PVRIG ligand expressed in PD-L1 positive and negative tumors PVRIG-/- knockout mice have reduced tumor growth Potential monotherapy, dual and triple combination therapy with PD-1 and/or TIGIT blockers Martinet & Smyth, 215 (modified) 9 9 9
10 COM71: PVRIG CHECKPOINT INHIBITOR From Computer Prediction to Functional Activity in Preclinical Models COM71 is a high affinity humanized IgG4 mab targeting PVRIG PVRIG identified as a novel immune checkpoint by Compugen and plays a unique role in the validated TIGIT axis COM71 is synergistic with anti-tigit and PD-1 pathway blockers as a potential cancer immunotherapy treatment First-in-class opportunities as monotherapy and dual/triple combination therapies IND FILING EXPECTED TOWARDS THE END OF Q
11 IF N (p g /m L ) IF N (p g /m L ) IF N (p g /m L ) IF N (p g /m L ) ENHANCED T CELL ACTIVATION BY COM71 ALONE AND IN COMBINATION WITH ANTI-PD-1 +/- ANTI-TIGIT Anti-TIGIT combination T a r g e t C e ll: P a n c T u m o r c e lls T c e ll: C M V p p 6 5 s p e c ific C D 8 T c e lls Anti-PD1 combination T a r g e t c e ll: C o lo 2 5 T u m o r c e lls T c e ll: C M V p p 6 5 s p e c ific C D 8 T c e lls Triple combination % % % % % % % % % % + 8 % % 1 1 h Ig G 4 C O M 7 1 T IG IT C O M T IG IT P D -1 h Ig G 4 C O M 7 1 T IG IT C O M T IG IT P D -1 h Ig G 4 C O M T IG IT C O M P D -1 T IG IT + P D -1 C O M T IG IT + P D -1 COM71 IN VITRO EFFECTS MATCH PD-1 INHIBITOR 11 11
12 TUMOR GROWTH REDUCTION AND INCREASED SURVIVAL * * * WITH PVRIG AND PD-1 PATHWAY BLOCKADE CT26 syngeneic model Tumor growth Survival T im e V o lu m e m m 3 P e rc e n t s u rv iv a l V o lu m e m m P e rc e n t s u rv i D a y s * * * p =. 5 ; T G I= 5 6 % m Ig G 1 + rig G 2 b 1 5 * p =. 4 4 ; T F = 4 /1 * P D L -1 + rig G 2 b P D L m P V R IG T im e * * * αpdl-1+rlgg2b αpdl-1+α-mpvrig m m m m D a y s * * * p =. 5 ; T G I= 5 6 % 12 D a y s D a y s 12 12
13 T u m o r v o lu m e (m m 3 ) T u m o r v o lu m e (m m 3 ) T u m o r v o lu m e ( m m 3 ) T u m o r v o lu m e (m m 3 ) T u m o r v o lu m e (m m 3 ) TUMOR GROWTH REDUCTION IN PVRIG KNOCK OUT ENHANCED IN COMBINATION WITH PD-1 PATHWAY BLOCKERS WT = wild type KO = knockout M C 3 8 W ild -ty p e v s 2 9 K O WT 5 M C 3 8 W ild -ty p e r Ig G 2 b PVRIG KO M C K O r Ig G 2 b W ild -ty p e r Ig G 2 b 2 9 K O r Ig G 2 b 4 3 D e a d 4 3 W ild -ty p e a n ti-p D L K O a n ti-p D L 1 2 D e a d 2 3 WT D a y s p o s t-tu m o r im p la n ta tio n 1 D e a d D a y s p o s t-tu m o r im p la n ta tio n 1 5 WT + anti-pd-l1 PVRIG KO PVRIG KO + anti-pd-l1 WT + anti-pd-l1 M C W ild -ty p e a n ti-p D L 1 PVRIG KO + anti-pd-l1 M C K O a n ti-p D L D a y s p o s t-tu m o r im p la n ta tio n D e a d D a y s p o s t-tu m o r im p la n ta tio n D a y s p o s t-tu m o r im p la n ta tio n Ganguly and Pardoll, Johns Hopkins Univ. MC38 model 13 13
14 SYNERGISTIC REDUCTION IN TUMOR GROWTH TIGIT KNOCKOUT PLUS PVRIG BLOCKADE Tumor growth; B16 model 3 WT + migg1 WT + α-mpvrig m m B16-Dbgp1 model * TIGIT KO + migg TIGIT KO + α-mpvrig 5 m m 3 m m D a y s m m 3 m m 3 3 D a y s D a y s D a y s D a y s * p <.5 ANOVA W T + m Ig G 1 T IG IT K O + m Ig G 1 W T + -m P V R IG T IG IT K O + -m P V R IG TGI compared to WT + migg1 Day 11 Day 14 Day 18 WT+ α-mpvrig 17% 13% 8% TIGIT-KO + migg1 17% 17% 13% TIGIT-KO 14 + α-mpvrig 63% 53% 49% 14 14
15 BIOLOGIC RATIONALE DRIVES COM71 CLINICAL DEVELOPMENT STRATEGY Tumor/ APC PVRL2 PVR DNAM PVRIG TIGIT T Cell - PD-1 PD-L1 Tumor/ APC INTERACTIONS OF THE PD-1 AND TIGIT/PVRIG PATHWAYS SUPPORT DRUG COMBINATION APPROACH 15 15
16 COM71 CLINICAL DEVELOPMENT STRATEGY Goal is to significantly expand the number of patients responsive to PD-1 blockade Targeting refractory and relapsing patient populations Potential to treat multiple patient populations based on expression Opportunities in lung, ovary, breast, endometrial, kidney, head & neck First-in-class opportunities as monotherapy and in combinations Biomarker strategy: enrich for patients most likely to respond Select patients with tumors where PVRIG, TIGIT pathways may be dominant Refractory & Relapsing Patients PD-L1 high Responsive Tumors (NSCLC, RCC) COM71 + PD-1 ± COM92 Naïve & Refractory & Relapsing Patients PD-L1 low/neg Poorly Responsive Tumors (Ovarian, TNBC, HNSCC) COM71 ± COM92 Naïve Patients PD-L1 low/neg Non-Responsive Tumors (MSS CRC) COM71 ± COM
17 STAGE 1C STAGE 1B STAGE 1A COM71 PHASE 1 CLINICAL STUDY COM71 Phase 1 First-in-man 3-stage design Oncology Single agent, Simon 3x3 dose escalation Safety, tolerability, PK/PD, clinical activity All-comers trial; no pre-selection Progressed on SOC Maximum Tolerated Dose (MTD) COM71 in combination with anti-pd-1 Safety, tolerability, PK/PD, clinical activity Rolling delayed start, 1 level highest safe 1A dose Combined w/ fixed dose of anti-pd-1 Current PK data suggest every 3 week dosing Select expansion cohorts in specific indications 2-3 patients per cohort COM71 in combination with anti-pd-1 Monotherapy indications (pending 1a response) Safety, tolerability, PK/PD, clinical activity 17 17
18 COM92 COMBINATION WITH COM71 TIGIT identified as a putative immune checkpoint by Compugen s predictive discovery platform in 29 (N. Stanietsky et al PNAS 29) Potential best-in-class anti-tigit antibody, COM92, has high (femtomolar) binding affinity Combination of COM71 and COM92 antibodies provides potential unique clinical differentiation In vitro effects of TIGIT/PVRIG blockade equal or exceed those seen with PD-1 combinations Process development and manufacturing agreement with Bayer to produce COM92 COM92 CMC ACTIVITIES ONGOING; IND EXPECTED IN
19 TAPPING INTO THE WORLD OF MYELOID TARGETS The Next Wave of Cancer Immunotherapies COM71 Tumor/ APC PVRL2 DNAM PVR COM92 PVRIG TIGIT T Cell - PD-1 CGEN-XXXX PD-L1 Tumor/ APC TARGETING MYELOID BIOLOGY OFFER COMPLEMENTARY THERAPEUTIC APPROACHES TO CHECKPOINT INHIBITORS 19 19
20 MYELOID TARGETS: MULTIPLE MOAs FOR EFFICACY AND ANTI-TUMOR IMMUNE RESPONSE Myeloid biology blockade offers potential for efficacy in Patients with strong immunosuppressive tumor micro-environment ( cold tumors ) Patients refractory to available checkpoint inhibitors A limited number of programs in development for known targets CD47, SIRPα, CD4, CSF1R Myeloid Antibody MoA Cell Depletion NK 2 2
21 ** ** MYELOID TARGET EXAMPLE #1: CGEN-1532 KNOCKOUT REDUCES TUMOR GROWTH AND SUGGESTS MONOTHERAPY APROACH CGEN-1532 CGEN-1532 * P<.5 ** P<.1 46% TGI KO vs. WT 49% TGI rigg2b vs. PDL-1 43% TGI WT+ PD-L1 vs. KO+ PD-L1 Ganguly and Pardoll, Johns Hopkins Univ. MC38 model 21 21
22 Donor 2 Donor 1 MYELOID TARGET EXAMPLE #2: INHIBITS T CELL ACTIVATION SIMILAR TO PD-L1 CHO-S acd3 (OKT3) TCR Target #2 Counterpart + - T cells Target 2 Target 2 n=8 donors; p<.5 for CD4 & CD8 proliferation, IFN, TNFa and IL
23 MYELOID TARGET EXAMPLE #2: OPPORTUNITY TO TREAT PD-1 INHIBITOR RESISTANT PATIENT POPULATION Target 2 + Target 2 + Target 2 - Target 2 - % Samples 23 23
24 CANCER IMMUNOTHERAPY COLLABORATION WITH BAYER Collaboration and License Agreement, signed August 213 CGEN-151T - NOVEL IMMUNE CHECKPOINT From computer prediction to functional activity in preclinical models Preclinical development on track Pivotal (GLP) toxicity studies ongoing GMP clinical trial material production ongoing $1M* upfront payment $15M Preclinical milestone payments to date Over $25M in potential milestone payments Royalties on global net sales: mid-to-high single digit * Received 24 for CGEN151T and CGEN
25 CGEN-151: FIRST-IN-CLASS THERAPEUTICS INDUCING TOLERANCE IN AUTOIMMUNE DISEASES CTLA4-lg (Orencia ) Fc fusion CGEN-151T mab CGEN-151 Fc fusion Compugen retained all rights to develop Fc-fusions for autoimmune indications counterpart IMMUNE TOLERANCE MECHANISM REPRESENTS NEXT GENERATION TREATMENT FOR AUTOIMMUNE DISEASES 25 25
26 CGEN-151 DIFFERENTIATION AND VALUE PROPOSITION Addressing widely anticipated next step therapeutic revolution in autoimmunity Tolerance induction and restoration of immunologic homeostasis in immune diseases First-in-class therapeutic agent of a novel inhibitory checkpoint pathway Clinical and commercial opportunities in multiple autoimmune diseases Paradigm shift from standard of care Tolerance induction offers safety advantages vs. immune-suppression Potentially efficacious in patients with inadequate response to standard of care 26 26
27 Number of Donor Tregs (x1 6 ) C lin ic a l S c o re CGEN-151: ROBUST EFFICACY IN MULTIPLE ANIMAL MODELS Short Term Treatment Consistently Leads to Durable Effect EAE: Multiple Sclerosis 3.5 Rx CIA: Rheumatoid Arthritis 6 P B S 5 C G E N E n b re l 4 NOD: Type 1 Diabetes Rx A rth ritis D a y Miller and Podojil, Northwestern Univ. Williams and McNamee, Univ. of Oxford, UK Miller and Podojil, Northwestern Univ. HY Mismatch: Bone Marrow Transplantation Number of Regulatory T cells in Spleen Miller and Podojil, Northwestern Univ. INTENTION TO PARTNER CGEN-151, TO FOCUS RESOURCES ON DEVELOPING IMMUNO-ONCOLOGY PRODUCTS 27 27
28 COMPUGEN: FOUR INTERNAL PROGRAM AREAS COM71 Anti-PVRIG mab drug candidate for cancer immunotherapy First-in-class advantage Novel checkpoint in TIGIT pathway Patent issued through Cancer Moonshot program Synergy with both -PD-1 and -TIGIT Myeloid Targets Complementary portfolio to T cell checkpoint programs for cancer immunotherapy Enhanced anti-tumor response through inhibition of immunosuppressive myeloid activity Multiple programs in progress COM92 Anti-TIGIT mab drug candidate for cancer immunotherapy Potential best-in-class mab with high (femtomolar) affinity Synergizes with COM71 and PD-1 pathways blockers CGEN-151 Fc fusion protein drug candidate for autoimmune diseases Unique immune tolerance mechanism Broadly applicable in RA, MS, T1D Durable response following short-term treatment in preclinical models 28 28
29 KEY STRATEGIC ADVISORS Industry Veterans, Renowned Oncologists and Immunologists SCIENTIFIC ADVISORY BOARD Drew Pardoll, MD, PhD Chairman of the SAB Antoni Ribas, MD, PhD STRATEGIC ADVISORS Elliott Sigal, MD, PhD Former CSO, EVP and Director Multi-year strategic collaboration Charles Drake, MD, PhD Iain McInnes, MD, PhD Steven Holtzman President and CEO, Decibel Therapeutics Former CBO and CEO Miriam Merad, MD, PhD Multi-year strategic collaboration Howard Soule, PhD Richard Haiduck Former CBO and CEO Life science companies 29 29
30 LEADERSHIP TEAM MANAGEMENT TEAM BOARD OF DIRECTORS Paul Sekhri Chairman of the Board Anat Cohen-Dayag, PhD President & CEO Ari Krashin Chief Financial & Operating Officer Kirk A. Christoffersen Senior VP - Corporate & Business Development Anat Cohen-Dayag, PhD President & CEO, Director Yair Aharonowitz, PhD Director Ruth Arnon, PhD Director Zurit Levine, PhD VP, Research & Discovery John Hunter, PhD VP, Antibody R&D and Site Head Compugen USA, Inc. Yona Geffen, PhD VP, Research & Validation Martin S. Gerstel Director Dov Hershberg Director Arie Ovadia, PhD Director Tsipi Keren-Lehrer VP, Business Development Dorit Amitay VP, Human Resources Michal Preminger, PhD, MBA Director Joshua Shemer, MD Director 3 3
31 FINANCIAL POSITION Cash Balance Gross Cash Expenditures* Market Capitalization ~$153 million (October 217) $38.5 million (September 3, 217) No Debt ~$8.5 million/quarter 217 quarterly forecast * Does not include cash receipts from any source NASDAQ (CGEN) NBI (Nasdaq Biotech Index) TASE (CGEN.TA) TA-9, TA-125, TA-Biomed, TA Global BlueTech, TA Tech-Elite 31 31
32 FROM CODE TO CURE TM Corporate Overview November 217 Anat Cohen-Dayag, PhD President & CEO 32
FROM CODE TO CURE. Corporate Overview. January Anat Cohen-Dayag, PhD President & CEO.
FROM CODE TO CURE TM Corporate Overview January 218 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of
More informationFROM CODE TO CURE. Corporate Overview. April Anat Cohen-Dayag, PhD President & CEO.
FROM CODE TO CURE TM Corporate Overview April 218 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of
More informationFROM CODE TO CURE. Corporate Overview. June Anat Cohen-Dayag, PhD President & CEO.
FROM CODE TO CURE TM Corporate Overview June 218 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. January 2012
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer January 2012 Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 1 Forward-Looking Statement Disclosure Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends,
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationAdvanced Epigenetic Technology BIO-Europe Spring 2018 Amsterdam, The Netherlands
Advanced Epigenetic Technology BIO-Europe Spring 2018 Amsterdam, The Netherlands March 13 th Zenith Profile Founded Company Status Products and Technology Location Financing 2014-2016 Shares Outstanding
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationPreclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial
Preclinical Assessment of JTX-211, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial Jennifer Michaelson, Ph.D. AACR Annual Meeting April 2, 217 Major Symposium Emerging
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCompany Presentation. September 2018 NASDAQ: VBLT
Company Presentation September 2018 NASDAQ: VBLT Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vascular Biogenics
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationIncyte Corporation. Hervé Hoppenot President & CEO. 34th J.P. Morgan Annual Healthcare Conference January 11, 2016
Incyte Corporation Hervé Hoppenot President & CEO 34th J.P. Morgan Annual Healthcare Conference January 11, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters
More informationOncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016
OncoMed Pharmaceuticals Jefferies Healthcare Conference Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 Safe Harbor Statement These slides and accompanying oral presentation
More information